Livongo Health Inc

NASDAQ:LVGO   3:59:59 PM EDT
59.30
-0.63 (-1.05%)
StockTwits Share  Twitter Share  Facebook Share

Livongo (NASDAQ:LVGO) Reports Fourth Quarter and Full Year Financial Results





Date Published:
Author: CMLviz News

 

 

Q4 Results

Revenue: $50.4 million (up 137% year-over-year) vs analyst expectations of $48.9 million

Adj EPS: -$0.06 vs analyst expectations of -$0.05

 

Full Year 2019 in Review

Revenue: Total revenue for the year was $170.2 million, up 149% year-over-year, and exceeding guidance range of $168.5 million to $169.0 million.

Livongo for Diabetes Members: 222,700 Members as of December 31, 2019, up 96% year-over-year.

Livongo Clients: 804 Clients as of December 31, 2019, up 95% year-over-year.

Customers: 30% of Fortune 500 companies vs 20% last year

Estimated Value of Agreements (EVA)$76.7 million, up from $56.1 million in the fourth quarter of 2018. It consists of the estimated value of agreements signed in the quarter with new Clients or expansions entered into with existing Clients.

 

Q1 Guidance

Revenue: $60 million - $62 million vs analyst expectations of $57 million

 

Full Year 2020 Guidance

Revenue: $280 million-$290 million (revenue to grow between 65% and 71%) vs analyst expectations of $277.5 million

 

Did You Know... LVGO is  on our list, and there are 19 more...

It’s finding the technology gems before they are  household names, that can turn into the 'next Google,’ or 'next Apple,’ where we have to get ahead of the curve. This is what CML Pro does, with an auditor verified performance track record, because of course it's verified.

Each company in our 'Top Picks’ has been selected as a future crown jewel of technology. Market correction or not, recession or not, the growth in these areas is a near certainty.

The precious few thematic top picks, research dossiers, and alerts are available for a limited time at a 30% discount.